CureVac (CVAC) Investor Presentation summary

Corporate strategy and transformation

• Initiated comprehensive organizational redesign in 2024 to streamline operations and improve efficiency, including a voluntary leaver program and unified leadership for R&D and clinical development.

• Focused on financial discipline, reducing OPEX, and extending cash runway into Q4 2025.

• Added new CEO and CDO, strengthening management expertise.

• Maintains strong cash position of €300.2 million as of March 31, 2024.

Pipeline and clinical progress

• Advanced infectious disease programs with promising Phase 2 data for COVID-19 and seasonal flu, and initiated new Phase 1/2 avian flu study.

• Oncology pipeline strengthened by collaboration with MD Anderson and progress in Phase 1 glioblastoma study.

• Diversified portfolio includes prophylactic vaccines, oncology, and molecular therapies, with multiple candidates in clinical and preclinical stages.

Technology and innovation

• Proprietary mRNA technology platform optimized for translation efficiency and immunogenicity, enabling low-dose, multivalent vaccines.

• Unique mechanism of action induces strong antibody and T cell responses, supporting both infectious disease and cancer vaccine applications.

• The RNA Printer® enables flexible, automated, GMP-grade mRNA manufacturing for personalized and small-scale needs.